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Varicose veins are the most frequent manifesta-
tions of chronic venous insufficiency (CVI), which
increases in incidence with age and whose estimated
rate of occurrence can vary worldwide from 10% to
50%. The dilatation of veins appears to be a primary
process that is initiated by unknown factors.1 There
are several theories about the possible mechanisms
that initiate the disease process.2 One of the more
often evoked theories concerns the weakness of the
venous wall, which in turn leads to the separation of
the valve cusps with consequent blood reflux. By
acting on the vein wall, this hemodynamic change,
and particularly high reverse flow velocity and tur-
bulence, facilitates an extensive tissue remodeling.2-6
In support of this hypothesis, evidence is accu-
mulating that implicates a deficient smooth muscle
function in the pathogenesis of CVI. For instance, it
was reported that the maximal responses of a varicose
vein preparation to norepinephrine (NE) and to
endothelin-1 (ET-1) are lower than those of control
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Purpose: Smooth muscle reactivity is one of the factors involved in the pathogenesis of
varicose veins. We investigated the myotropic effects of the 3 main vasoconstrictor
agents—norepinephrine (NE), angiotensin II (Ang II), and endothelin-1 (ET-1)—in
isolated human saphenous veins.
Methods: Human saphenous veins were collected from 23 patients with primary chronic
venous insufficiency who underwent elective varicose vein resections and who were strati-
fied into the following 3 groups: group 1, 7 patients in clinical class 2; group 2, 9 patients
in clinical classes 3 and 4; and group 3, 7 patients in clinical classes 5 and 6. Moreover, 6
patients who underwent arterial bypass grafting procedures represented the control group.
The tissues were suspended in organ baths that contained Krebs solution, and their
mechanical responses were measured isometrically. The cumulative concentration–response
curves to Ang II, NE, and ET-1 were performed at 90-minute intervals in each tissue.
Results: In the control tissues, NE, Ang II, and ET-1 induced concentration-dependent con-
tractions with apparent affinities (pEC50, the negative logarithm to base 10 of the molar
concentration of the agonist, which produces the 50% of the maximal effect) and maximal
effects (maximum effect, g of contraction) that were equal to 7.06 ± 0.23, 8.53 ± 0.34, 7.63
± 0.10, and 2.21 ± 0.33, 1.65 ± 0.31, 2.60 ± 0.77, respectively. Two main findings were
evident in comparison of varicose veins with control tissues. First, the maximum effect that
was evoked by all of the stimulants was reduced progressively with the increasing severity of
the disease, which raised the third group to statistical significance for both NE and Ang II
(P < .05). Second, a marked reduction of Ang II apparent affinity was already evident in tis-
sues that were taken from patients in an early stage of the disease (P < .05).
Conclusion: The demonstration of a significant reduction in Ang II and NE contractile
activities and the important reduction of that of ET-1 in the diseased veins as compared
with the control tissues extends the previous observations regarding the impairment of
smooth muscle contractility in primary chronic venous insufficiency. Moreover, the dra-
matic reduction of Ang II affinity, which appears in an early stage of the disease, sup-
ports the hypothesis that such abnormality within the venous wall could play a role in
the pathogenesis of primary varicose vein disease. (J Vasc Surg 1998;28:855-61.)
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healthy tissues.3,7-9 Whether these functional changes
cause a multifocal impairment of vein smooth muscle
and mediate the development of varicose veins or
merely represent an epiphenomenon of the patho-
physiologic process still remains a contentious issue.
The aim of the present study was the comparison
of the myotropic effects of the 3 main endogenous
vasoconstrictor agents—NE, ET-1, and angiotensin
II (Ang II)—along the natural history of primary
varicose veins disease (PVV). The effects of these
agents were tested in saphenous vein tissues that
were obtained both from patients with PVV of dif-
ferent clinical classifications and from subjects with-
out any evidence of coexistent venous disease (the
control group). The testing was performed to recon-
struct the stage in which the changes in contractile
response become evident along the progressive
course of the disease.
MATERIALS AND METHODS
Patient population. The proximal portion of
the greater saphenous vein (GSV) was obtained
from 23 patients (7 men, 16 women; mean age, 51
± 11 years) who were referred to our vascular labo-
ratory for PVV and from 6 patients (6 men; mean
age, 62 ± 6 years; controls) who underwent a limb
salvage procedure with in situ saphenous bypass
grafting. The patients for varicose veins with a com-
petent proximal tract of the GSV, with post-phlebitic
and congenital venous disease, were excluded from
the present study. The selection was made in accor-
dance with the clinical and duplex criteria stated
below. The patients for PVV were separated into 3
distinct clinical groups of increased severity of the
disease on the basis of the clinical, etiologic, anatom-
ic, and pathophysiolobic (CEAP) classification. The
CEAP classification is summarized in Table I.10
The diagnosis of varicose vein disease was made
with the combination of clinical examination (positive
Trendelenburg’s test and Perthes’ test) and duplex
scanning examination (Ansaldo AU 4, 7.5 to 10
MHz, Esaote Biomedica, Genova, Italy). Superficial
vein incompetence was diagnosed when a reverse flow
longer than 0.5 seconds11,12 was detected in at least 1
saphenous segment, with the Doppler scan sample
volume placed at an angle of 45 degrees at 5 different
levels along the GSV and the saphenofemoral junc-
tion. Reflux was evoked through manual calf squeez-
ing in the patient who was standing; the manual
squeezing maneuver always was performed by the
same investigator (P.Z.). Duplex analysis also investi-
gated the common and the superficial femoral veins.
The investigation of the popliteal region included the
saphenopopliteal junction, the proximal tract of the
lesser saphenous vein, the gastrocnemius vein, and the
popliteal vein from the junction level to the opening
of the anterior/posterior tibial vein. When an unsatis-
factory image of the anterior/posterior tibial vein was
obtained, the veins were studied distally. Finally, the
perforating vein system was investigated in accor-
dance to the duplex scan methodology that was
described by Labropoulos et al.13
We also investigated the disease duration in the
selected patients, which was self-assessed by the
patients through the date of onset of visible varicose
veins or of typical symptoms of CVI. Because of the
admitted unreliability in the determination of dis-
ease duration with a single question, the physicians
spent some time in assessing the disease duration
with a series of other questions to relate the appear-
ance of CVI symptoms or varicose veins with other
precise life events.
The patients gave informed consent, and the
protocol was approved by the Ethics Committee of
our hospital. The selected patients underwent air-
pletysmographic examination (APG)14,15 for the
assessments of total volume, venous filling index
(VFI), ejected fraction, and residual volume fraction
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Table I. Characteristics of the selected patients divided into 3 groups of increasing severity of disease on
the basis of the CEAP classification
C E A P
Group 1 C2s 7 patients Primary 7 patients S2, P17 5 patients Reflux 7 patients
S2-S3, P17 1 patients 
S2-S3, P17-18 1 patients
Group 2 C3s 7 patients Primary 9 patients S2, P17 1 patient Reflux 9 patients
C4s 2 patients S2-S3, P17 2 patients 
S2-S3, P17-18 6 patients
Group 3 C5s 5 patients Primary 7 patients S2-S3, P18 2 patients Reflux 7 patients
C6s 2 patients S2-S3, P17-18 5 patients
C, Clinical; E, etiologic; A, anatomic; P, pathophysiologic.
(RVF). The APG examination was performed in all
of the cases between 8 AM and 10 AM at the same
temperature (23°C) before the surgery was per-
formed for the correction of CVI.
Tissue collection. The patients in the control
group were affected by critical limb ischemia and did
not have any clinical history or evidence of venous
disease. All of the patients underwent in situ
femorodistal bypass graft procedures, and the strip
of the saphenous vein, which was never shorter than
1 cm, was taken from the junction level just before
performing the proximal anastomosis. Pathologic
saphenous vein samples were obtained during
surgery for superficial venous insufficiency. The sam-
ples were taken from the junction at the time of
saphenofemoral disconnection and carefully excised
with direct visualization.
Tissue preparation. After the surgery, the seg-
ments of human saphenous vein (hSV) were placed
in a cold Krebs solution (4°C). The lapse of time
between the surgery and the experiment was 15
hours on the average. 
In the preliminary experiments, we tested the con-
tractile responses of the same vein to different agents
immediately after the surgery (delay, 0 hours) and
after a 24-hour stay in a cold Krebs solution (4°C).
No significant differences were found between the 2
sets of data. These data indicated that the lapse of
time between the surgery and the experiment did not
influence the results of the experiments.
In the laboratory, the tissue was placed in a Krebs
solution at room temperature and, within 30 minutes,
the vein was dissected free of surrounding tissues. The
tissues then were cut into open rings (2 to 4 rings for
each vein), mechanically denuded of their endotheli-
um, and suspended in 10-mL organ baths that con-
tained a Krebs solution that was gassed with 95% O2
and 5% CO2 (pH, 7.4). The strips were preloaded
with 1 g. The mechanical responses were measured
isometrically by Grass FT03 force transducers (Selb,
Germany) and recorded on a Linseis multichannel
chart recorder (model 2005, Selb, Germany).
Experimental protocol. After an equilibration
period of about 2 hours, the preparations were con-
tracted with KCl (100 mmol/L, standard stimulus).
The absence of relaxation to ACh (1 m mol/L) in tis-
sues that were precontracted by NE (1 m mol/L)
indicated the absence of a functioning endotheli-
um.16,17 The cumulative concentration–response
curves (CRCs) to Ang II, NE, and ET-1 were per-
formed at 90-minute intervals in each tissue. The
CRCs were obtained with the application of increas-
ing concentrations of agonists (0.5 logarithm unit
steps). The tissues did not loose contractility for 5 to
6 hours of in vitro incubation. This was established
in the preliminary experiments when we did not find
significant differences between the contractile effects
of 100 mmol/L KCl applied at the start and at the
end of the incubation period. This also was observed
in the tissues that were used to record CRCs to Ang
II and NE. All of the in vitro experiments were per-
formed by investigators who were unaware of the
clinical assessments of the patients from whom the
tissues were collected.
Materials. ET-1, Ang II, substance P, and
bradykinin were purchased from the American
Peptide Company (Sunnyvale, Calif). All of the
other substances and reagents were from the Sigma
Chemical Company (St Louis, Mo) or from E
Merck (Darmstadt, Germany). The stock solutions
(1 mmol/L) were made in distilled water and kept
at –20°C until use. The Krebs solution had the fol-
lowing composition (in mmol/L): NaCl, 118.5;
KCl, 4.7; MgSO4, 1.2; KH2PO4, 1.2; NaHCO3, 25;
CaCl2, 2.5; and glucose, 10.
Data analysis and terminology. All data are
expressed as the mean ± the standard error of the
mean. The difference in disease duration and in venous
function among clinical classifications were tested for
significance with 1-way analysis of variance followed by
the Student-Newman-Keuls test for multiple compar-
ison with a software package.18 Pharmacologic data
were statistically analyzed with 1-way analysis of vari-
ance followed by the Dunnett test for multiple com-
parison with a software package.18 P values that were
lower than .05 were considered to be significant. The
pharmacologic terminology that is adopted in this
paper is in accordance with the recent recommenda-
tions of the International Union of Pharmacology
Committee on Receptors Nomenclature and Drug
Classification.19 The agonist apparent affinities are
given as pEC50 = the negative logarithm to base 10 of
the molar concentration of an agonist that produces
50% of the maximal possible effect.
RESULTS
The patients with PVV were classified in accor-
dance with the new CEAP classification criteria10
that are summarized in Table I. The following clas-
sifications were seen: 7 patients had noncomplicated
but symptomatic varicose veins (clinical class, C2s;
first group of 7 patients); 7 patients had varicose
veins that were complicated by edema (clinical class,
C3s): and 2 patients had edema and skin changes
(clinical class, C4s): these classifications constitute
the second groupof 9 patients; 7 patients had healed
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or active ulcers (clinical class, C5s to C6s; third
group of 7 patients).
In all of the cases, the etiology was primary (Ep).
The anatomic (A) distribution of the disease is
detailed in Table I. Venous insufficiency confined in
the superficial system of the above-knee GSV terri-
tory is indicated by S2 and that of the below-knee by
S3. P17 and P18 indicate perforators insufficiency of
the thigh or calf territory, respectively. The patho-
physiology (P) of the disease was always as a result of
reflux. The following algorithm describes the
patients who are included in the present study:
C, 2s to 6s; Ep; A, S2 to S3; P17 to P18, Pr.
APG indices that were measured for all of the
patients (and divided in accord to clinical classifica-
tions and the disease duration, subjectly determined
as above described) are given in Table II. 
The first group of patients appeared to be in an
early stage of the disease. This is shown by the sig-
nificant differences that are observed in the total vol-
ume, the VFI, and the RVF values between group 1
on one side and groups 2 and 3 on the other. 
Functional in vitro assays showed that 1 mmol/L
of ACh, applied in veins that were previously contract-
ed with 1 mmol/L NE, did not induce any relaxation.
Similar results also were obtained with bradykinin or
substance P (both 100 nmol/L) as vasorelaxation
agents (data not shown). This data confirmed the
absence of functional endothelium in the strips.
In control tissues, 100 mmol/L of KCl induced
a rapid contraction that reached a plateau at 1.16 ±
0.28 g. In the same tissues, cumulative CRCs to NE,
Ang II, and ET-1 were performed at 90-minute
intervals. The 3 vasoconstrictor compounds induced
concentration-dependent contractions of hSV strips.
The contractions that were induced by NE and Ang
II were rapidly reversible after washing, and those
that were evoked by ET-1 were not reversible. For
this reason, the CRCs to ET-1 always were per-
formed at the end of the experiments.
A comparison of the contractile effects of KCl,
NE, Ang II, and ET-1, which were obtained in
saphenous veins from patients with PVV, and con-
trol is presented in Table III. The apparent affinities
of the agonist, which were expressed in terms of
pEC50 and maximal contractile responses (maxi-
mum effect [Emax], measured in g), have been used
to evaluate the effects of these substances on smooth
muscle fiber contractility. The data obtained with
KCl, the depolarizing nonspecific agent, indicate
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Table II. Results of air-plethysmographic examination determinations and of assessment of disease dura-
tion in patients with primary varicose vein disease stratified into 3 clinical groups of increasing severity
Total volume Venous filling index Ejection fraction Residual volume fraction Disease duration
(ml air) (ml air/min) (% of TV) (% of TV) (years)
Group 1 (clinical C2) 109 ± 36 2.2 ± 1.4 57 ± 21 23 ± 12 7 ± 4
Group 2 (clinical C3 to C4) 163 ± 50* 5.6 ± 1.6* 53 ± 9 33 ± 14 18 ± 6*
Group 3 (clinical C5 to C6) 177 ± 19* 6.2 ± 0.8* 48 ± 4 46 ± 3* 21 ± 3*
Normal values <150 <1.7 >70 <33
*P < .05 versus group 1.
Table III. Effects of KCl, norepinephrine, angiotensin II, and endothelin-1 in human saphenous vein
strips from control subjects and from patients with primary varicose vein disease in 3 groups of increasing
severity of the disease
Norepinephrine Angiotensin II Endothelin-1
KCl 100mM pEC50 Emax (g) pEC50 Emax (g) pEC50 Emax (g)
Group 1 (clinical C2) 1.44 ± 0.29 6.68 ± 0.27 1.96 ± 0.35 7.63 ± 0.29* 1.44 ± 0.27 7.53 ± 0.56 2.29 ± 0.42
Group 2 (clinical C3 to C4) 0.94 ± 0.23 6.54 ± 0.28 1.69 ± 0.32 7.42 ± 0.20* 0.74 ± 0.17 7.32 ± 0.51 2.02 ± 0.68
Group 3 (clinical C5 to C6) 0.44 ± 0.14† 6.81 ± 0.19 0.97 ± 0.16* 7.46 ± 0.27* 0.45 ± 0.15* 7.64 ± 0.45 1.02 ± 0.28‡
Control tissues 1.16 ± 0.28 g 7.06 ± 0.23 2.2 ± 0.33 8.53 ± 0.34 1.55 ± 0.31 7.63 ± 0.10 2.40 ± 0.57
*P < .05.
†P = .056.
‡P = .076 vs control group.
that the pathologic lesions of the veins reduce the
strip contractility (P = .056 in group 3, exactly at the
limit of significance). 
NE shows little if any changes of apparent affin-
ity, but the maximal contractile response to the cat-
echolamine is significantly reduced in the tissues of
group 3 (P < .05). Similar results, although not sta-
tistically significant, were obtained with ET-1, the
potent long-acting vasoconstrictor. The affinity of
this agonist is similar in the 4 groups of tissues, and
maximal contractility is slightly lower in the tissues
from group 2 but is reduced by half in patients of
group 3 (P = .076). The contractile responses to
Ang II were reduced in the tissues from all of the
PVV patients. The maximal effect that was induced
by the octapeptide was one half and one third of the
control values in the vein of groups 2 and 3, respec-
tively—the values of the latter being significantly dif-
ferent from the values of the control group. In addi-
tion, a dramatic reduction (more than 10-fold) of
Ang II pEC50 was observed between the control and
the diseased tissues. Interesting enough, the reduc-
tion of Ang II apparent affinity already was evident
and statistically significant in the tissues of group 1
as compared with the control group. Moreover, in
the diseased veins, the application of Ang II
induced, simultaneously with the increase of ten-
sion, spontaneous activity of the tissues (rhythmic
spikes). This phenomenon was never observed in the
control tissues or in the diseased tissues that were
stimulated by NE and ET-1. The results that are
summarized in Table III are illustrated in Fig 1 by
showing the mean ± the standard error of the mean
of the CRCs for NE, Ang II, and ET-1 in the con-
trol and the diseased tissues.
DISCUSSION
The maintenance of the venous tone is expected
to be largely controlled by the sympathetic nerves,
by the autacoids, such as the endothelins, and by the
vasoactive hormones, such as angiotensin.3,7-9,20-23
The results that are presented above show that all of
these stimulants are capable of inducing concentra-
tion–dependent contractions in hSV tissues by act-
ing through different mechanisms: KCl 100
mmol/L, by inducing cell membrane depolariza-
tion; and NE, ET-1, and Ang II by activating specif-
ic receptors that are located in the smooth muscle
cells of the hSV. It has been shown that in this
preparation Ang II acts via angiotensin receptor-1
receptors,22 and NE and ET-1 exert their contractile
activities by activating a mixed population of a 1-
a 221 and ETA and ETB receptors,8,23 respectively.
The values of apparent affinity (pEC50) that are
measured in the control tissues (7.06, 8.53, and
7.63 for NE, Ang II, and ET1, respectively) are
close to those that are obtained with similar experi-
mental conditions by other authors—NE 7.25,21
Ang II 8.61,22 and ET-1 8.06.23 Thus, the present
data are in concord with the current literature.
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Fig 1. A, Concentration response curves to norepineph-
rine (NE), B, angiotensin II (Ang II), and C, endothelin
1 (ET-1) in human saphenous veins from control subjects
and from patients with primary varicose vein disease.
Abscissa, logarithm of the molar concentration of agonist;
ordinate, tension in g.
The comparison between the responses of the
control tissues and those that were obtained in dis-
eased tissues indicates that the following two differ-
ent phenomena occur during the natural history of
PVV: first, a nonspecific loss of contractility of vein
strips, which appears only in the late phases of the
disease; and second, a dramatic decrease of sensitivi-
ty to Ang II, which occurs in an early stage of PVV.
The loss of contractility of the PVV strips is doc-
umented by the reduction of Emax induced by NE,
Ang II, and ET-1 and by the reduction of the con-
tractile effect of 100 mmol/L KCl. Moreover, this
decrease in contractility is not present in group 1
(clinical class C2) but becomes evident in group 2
(C3 to C4) and important in group 3 (C5 to C6),
where the level of significance is raised for both NE
and Ang II. In addition, the important decline of
contractility in response to ET-1, although not sig-
nificant (P = .076), confirms the progressive wors-
ening of the vein wall properties with the increasing
severity of the disease. 
These results can be easily interpreted on the
basis of the well known remodeling phenomenon.
In the comparison of normal and varicose vein walls,
both the histologic and biochemical data showed an
extensive tissue remodeling, with the latter exhibit-
ed by increased levels of plasminogen activator.24
The most prominent histologic lesions that can be
seen in varicose veins is an increase in the fibrous
connective tissue of the media. There is also the sep-
aration of the smooth muscle cells from one anoth-
er, and the elastic fibers tend to spread throughout
the vein wall instead of being confined to the inter-
nal or external elastic lamina. These changes are gen-
erally patchy: electron microscopy of smooth muscle
cells shows them to contain collagen fibers, which
suggest that the smooth muscle cell has assumed
phagocytic properties. A decrease in the total
smooth muscle content also has been shown and is
considered to be one of the signs of the disease pro-
gression within the vein wall in varicose condi-
tions.4-5,8,24-26
The functional changes that we attempted to
evaluate in the present study with vasoconstrictors
are in accordance with the histologic picture of
remodeling, which is outlined above. In fact, Emax
is expected to provide a rough measurement of mus-
cle receptor numbers, and pEC50 reflects the inter-
action of the agent with the receptor and gives an
estimate of individual receptor function. The results
of the present investigation clearly indicate that
Emax is reduced for all vasoconstrictors and that the
reduction is progressively more evident with the
gravity of the disease. In group 3, Emax: 1), reaches
the level of significance for NE and Ang II; 2), is at
the limit of significance for KCl; and 3), is less than
half of the control values for ET-1.
Thus, the remodeling of the muscle layer may
impair the vasoactive agents–mediated contractility
and appears to be reflected by the decrease in recep-
tor numbers and Emax, especially in the late phases of
the disease. Conversely, the receptors appear to inter-
act efficiently with the vasoconstrictors, at least with
NE and ET-1, because the pEC50 values for these
agents do not change with the severity of the disease.
The present results confirm the findings of a
recent study by a group of investigators from the
Mayo Clinic. By measuring receptor binding, Barber
et al9 found that the number but not the affinity of
ET-1 receptors was diminished in the tissues of PVV.
They concluded that, as the veins become varicosed,
there is a specific loss of receptors for ET-1.
On the contrary, the decrease in the apparent
affinity for Ang II is already present in the tissues
from group 1 and is found in the other groups with-
out further aggravation. The patients of group 1 had
a short disease duration and had no significantly
altered venous function as shown in Table II. In fact,
the mild intensity of reflux that was expressed by the
VFI index shows that little hemodynamic changes
have occurred. In addition, the acceptable calf pump
function, expressed by ejected fraction and partially
by RVF values, suggests that no extra vascular fac-
tors are involved in the pathogenesis of CVI in this
group of patients. Therefore, neither clinical nor in
vitro signs of extensive remodeling are evident.
The decrease of affinity, specific for Ang II, may
be interpreted by assuming that, in diseased tissues,
changes occur at the Ang II receptor level. These
receptors become more than 10-fold less sensitive to
the agonist and their ability to induce contraction is
not changed (the Emax in control tissues and in tis-
sues of group 1 is not different). Such changes can-
not be explained by a reduced accessibility of Ang II
to its receptor because tissues of group 1 show little
if any signs of remodeling. Accentuated local enzy-
matic degradation of Ang II seems unlikely, but no
data are available to exclude this possibility. The
intracellular smooth muscle machinery that sub-
serves contraction appears to be efficient because
NE and ET-1 and also high concentrations of Ang II
evoke maximal contractions. The alteration is there-
fore to be placed at the level of the Ang II–receptor
interaction. The present data cannot clarify whether
such an alteration is just an epiphenomenon or is a
primary defective mechanism (probably genetically
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determined) that is involved in the pathogenesis of
the disease. Worthy of mention is the familial distri-
bution of the disease: Cornu-Thenard et al27 found
that the risk of suffering from PVV for children was
90% when both parents were affected, 25% for male
patients and 62% for female patients when one par-
ent had this disease, and only 20% when neither par-
ent was affected. 
Taken together, the present findings support the
intriguing hypothesis that a primary defective mech-
anism in the Ang II–mediated control of the venous
tone could play a role in the pathogenesis of CVI. In
consideration of the primary role that is played by the
renin-angiotensin system in cardiovascular patho-
physiology, these findings could have important
implications for drug development and therapeutic
uses, particularly of angiotensin converting enzyme
inhibitors and angiotensin receptor antagonists.
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